Andrea Tu, Author at Bolt Biotherapeutics - Page 3 of 6

About Andrea Tu

This author has yet to write their bio.
Meanwhile lets just say that we are proud Andrea Tu contributed a whooping 52 entries.

Entries by

Press Release

June 9, 2020 in press release /by Andrea Tu

Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody™ ISAC Technology and its Lead Development Candidate, BDC-1001

Publication

June 8, 2020 /0 Comments/in publications /by Andrea Tu

Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Presented at: 2020 San Antonio Breast Cancer Symposium

Press Release

May 12, 2020 in press release /by Andrea Tu

Bolt Biotherapeutics Appoints William P. Quinn as Chief Financial Officer

Press Release

April 9, 2020 in press release /by Andrea Tu

Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer

Past Event

April 3, 2020 in events /by Andrea Tu

Bolt invited to present: 2020 Jefferies Virtual Healthcare Conference June 3, 2020

Press Release

April 2, 2020 in press release /by Andrea Tu

Bolt Biotherapeutics Appoints Nathan Ihle, Ph.D., as Vice President of CMC and Quality

Media Coverage

March 30, 2020 in media coverage /by Andrea Tu

Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors Precision Oncology News

Press Release

March 26, 2020 in press release /by Andrea Tu

Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors

Media Coverage

March 10, 2020 in media coverage /by Andrea Tu

Bolt Bio Preps Clinical Trials of Immune-Stimulating Cancer Drug in Stubborn Solid Tumors FierceBiotech

Past Event

March 7, 2020 in events /by Andrea Tu